It hasn't been negotiated yet, nor have we received the agreement. We did, of course, receive a letter from the government informing us that our funding has been reduced by $860,000, which is a very significant amount for us.
At this time, the number of people on my team remains unchanged, and there will be no new hires.
However, we're definitely launching a new competition soon. Here's our plan. For the projects that will enter our therapeutic product pipeline, of which there are several and of different types, we'll likely have to cut one of the programs responsible for introducing new products into our pipeline. Of course, the goal is always to reach a clinical trial.
This will therefore have an impact on the support we're able to provide to our scientific community and the physicians we work with. Ultimately, it could also affect patients who, we hope, will receive these different types of products in the future.